Kymab strengthens management team
This article was originally published in Scrip
Executive Summary
Cambridge, UK-based Kymab, a monoclonal antibody biopharmaceutical company, has named Steve Arkinstall chief scientific officer and Nigel Clark president and head of business development. Mr Arkinstall joins the company from Merck Serono where he held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of global technologies and external innovation. He succeeds Allan Bradley as CSO at Kymab. Mr Bradley, a founder of the company, will remain on the executive leadership team.